Anlotinib combined with etoposide for platinum-resistant recurrent ovarian cancer: A case report

Abstract

Introduction: Platinum-resistant ovarian cancer is characterized by its poor prognosis and limited treatment options. Angiogenesis plays a fundamental role in the development of drug-resistance in ovarian cancer. Anlotinib, a novel oral multi-targeted tyrosine kinase inhibitor which targets a board spectrum of angiogenesis-associated growth factor receptors, has shown promising anti-tumor efficacy in clinical trials. Herein, we report a case of ovarian cancer treated with anlotinib plus etoposide after secondary cytoreductive surgery.

Patient concerns: A 45-year-old female with primary platinum-resistant ovarian cancer who progressed rapidly after the first cytoreductive surgery, the second cytoreductive surgery, and several lines of treatment. The patient refused to receive intravenous chemotherapy any more.

Diagnosis: Primary platinum-resistant ovarian cancer.

Interventions: The oral combination treatment of anlotinib (12 mg, qd) and etoposide (100 mg, qd) were delivered.

Outcomes: Finally, the patient was responsive to the orally treatment of anlotinib combined with etoposide. The patient has been alive with no evidence of disease progression for 18 weeks.

Conclusion: Our case suggests that oral treatment of anlotinib combined with etoposide which is acceptable and convenient, may be an additional option for the management of platinum-resistant ovarian cancer.

Figure 1

The levels of serum CA 125 of the patient.

Figure 2

CT image showing metastases before and during the treatment of anlotinib plus etoposide. CT image showing (A) lymph nodes metastases in the right inguinal region (C) liver metastases before treatment of anlotinib plus etoposide (October 9, 2018). CT image showing (B) smaller lymph nodes metastases in the right inguinal region (D) similar liver metastases after eleven weeks of anlotinib plus etoposide treatment (December 24, 2018).